Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.

Hongbin YiFenghao ShiZihao WangLiping KuaiDongyan XuYu XieHua Xing

Published in: BMJ open (2023)

Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare disease patients' access to these orphan drugs.

Keyphrases

end stage renal disease
drug induced
newly diagnosed
ejection fraction
adverse drug
chronic kidney disease
healthcare
emergency department
patient reported